Skip to main content
MarketsSingle-sourceLow
2.1

SEB raises Hansa Biopharma price target to 150 SEK, citing significant upside potential

SEB has increased its price target for Hansa Biopharma to 150 SEK, representing a 388% premium over the previous closing price. The bank cites a favorable risk-reward profile for the company's future development, though the extreme target suggests high volatility or a specific valuation model shift.

Dagens Industri2 days agoSECredibility 27%View source

Score Breakdown

Mosaic Score2.1
Confidence0.9
Significance0.1
Source credibility0.3

Intelligence Tags

Locations

Stockholm

Entities

country
Source

Related signals

8 found